MicuRX touts PhII on antibiotic candidate; Japan's Ono files NDA on carfilzomib;

> China-focused MicuRx Pharmaceuticals said it recorded "positive" top-line results from the first Phase II clinical study of lead drug candidate MRX-I, an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria. Funds for the Phase II came from Shanghai Zhangjiang Biomedical Industry Venture Capital. Release

> Japan's Ono Pharmaceutical filed a new drug application for carfilzomib, or ONO-7057, to treat relapsed or refractory multiple myeloma. The drug has already received orphan designation by Japan's Ministry of Health, Labor and Welfare. Release (PDF)

> China FDA has issued results from drug clinical trial data self-examination reporting that listed firms and actions taken including about 20% of the candidates deciding to withdraw candidates. Release (Chinese language)

> China FDA has issued new national rules for drug packaging materials and containers covering 130 standards that will come into effect at the start of December. Release

> China's Shanghai Kehua Bio-Engineering will buy Italy's Technogenetics from Bouty Healthcare to marry its IVD operations with the target company's diagnostic tests for autoimmune and infectious diseases, an investor relations official said. Investor relations

> China's Harbin Gloria Pharma will pay nearly $30 million for 70% of Sheyang Zhenyang Hospital as the maker of injectable drugs enters the medical services market as part of a strategic plan to further expand the pharmaceutical business. Release (Chinese language)

> India's Aurobindo Pharma received U.S. FDA approval for an amended new drug application for entecavir (Baraclude) tablets. Release (PDF)

> Market regulators in Shanghai fined Pfizer ($PFE) RMB100,000 ($15,570) for alleged payments to pharmacies to recommend its Viagra over other erectile dysfunction treatments, China Daily said. The company did not immediately respond for request to comment. Report

> China's Zhejiang Jingxin Pharma bought a 51% stake in U.S.-based CRO Pharmula Laboratories with financial details unclear. Release (Chinese language)

> HK-listed Golden Meditech Holdings announced the end of an agreement entered into between KKR China Healthcare Investment in respect to the purchase of the senior convertible notes issued by China Cord Blood Corporation to KKR. Release

> India's pharmaceutical market is seen as a $55.4 billion market opportunity by 2020, according to New Market Research. The market is projected to boast a compound annual growth rate of 18% on the back of an aging and growing population, rising income levels, emerging medical conditions and new diseases. Release

> China's WuXi AppTech ($WX) said its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical has received the first approval from Japan's Pharmaceutical and Medical Devices Agency to manufacture a GMP intermediate of a branded commercial drug in July. Report

> Australia's Admedus has adopted Medidata's cloud technology, Medidata Clinical Cloud, as part of its clinical development of a therapeutic vaccine for genital herpes (HSV-2), aimed at activating a T-cell response against the virus to benefit sufferers. Release

> A multinational coalition of drugmakers are working with the National Cancer Center of Japan to find new treatments based on an effort to collect genetic information from cancer patients to build a database for clinical trials, Nikkei Asian Review said. Report

> A Korean research team is looking at data that shows injections of adult mesenchymal stem cells (MSCs) may extend healthy life and lifespan by intravenous injections. The team from Chungbuk National University and Biostar said in a press release that the discovery was published in International Journal of Medicine, 'Stem Cells Translation Medicine' (IF 5.7) on Aug. 27, 2015. Release